Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer

Citations Over TimeTop 15% of 2009 papers

Abstract

Tristetraprolin (TTP) is an AU-rich element-binding protein that regulates mRNA stability. Here, we report that TTP suppress the growth of human colon cancer cells both in vivo and in vitro by regulating of the expression of vascular endothelial growth factor (VEGF). TTP protein expression in human colonic tissues was markedly decreased in colonic adenocarcinoma compared with in normal mucosa and adenoma. VEGF expression was higher in colonic adenocarcinoma than in normal mucosa and adenoma. Specific inhibition of TTP expression by RNA-interference increased the expression of VEGF in cultured human colon cancer cells, and TTP overexpression markedly decreased it. In addition, elevated expression of TTP decreased the expression level of luciferase linked to a 3' terminal AU-rich element (ARE) of VEGF mRNA. Colo320/TTP cells overexpressing TTP grew slowly in vitro and became tumors small in size when xenografted s.c into nude mice. These findings demonstrate that TTP acts as a negative regulator of VEGF gene expression in colon cancer cells, suggesting that it can be used as novel therapeutic agent to treat colon cancer.

Related Papers

• → Tristetraprolin Regulates the Expression of the Human Inducible Nitric-Oxide Synthase Gene(2005)100 cited
• → Tristetraprolin, a Negative Regulator of mRNA Stability, Is Increased in Old B Cells and Is Involved in the Degradation of E47 mRNA(2007)97 cited
• → Roles of Tristetraprolin in Tumorigenesis(2018)49 cited
• → Regulation of tristetraprolin during differentiation of 3T3‐L1 preadipocytes(2007)26 cited
• → Cinnamon and Immune Actions: Potential Role in Tristetraprolin-Mediated Inflammatory Diseases(2010)